首页> American journal of obstetrics & gynecology MFM> Azithromycin dosing and preterm premature rupture of membranes treatment (ADAPT): a randomized controlled Phase I trial.

Azithromycin dosing and preterm premature rupture of membranes treatment (ADAPT): a randomized controlled Phase I trial.

导出 LinkOut

翻译打印收藏纠错

第一作者： Rupsa C,Boelig

第一单位： Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College (Boelig); Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University (Boelig Kraft, and Lam), Philadelphia, PA. Electronic address: Rupsa.boelig@jefferson.edu.

作者： Rupsa C,Boelig ^[1] ; Kevin,Lam ^[2] ; Ankit,Rochani ^[3] ; Viren,Soni ^[4] ; Gagan,Kaushal ^[4] ; Walter K,Kraft ^[2]

作者单位： Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College (Boelig); Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University (Boelig Kraft, and Lam), Philadelphia, PA. Electronic address: Rupsa.boelig@jefferson.edu. ^[1] Department of Pharmacology, Physiology, and Cancer Biology, Sidney Kimmel Medical College, Thomas Jefferson University (Boelig Kraft, and Lam), Philadelphia, PA. ^[2] Wegmans School of Pharmacy, St. John Fisher University (Rochani), Rochester, NY. ^[3] College of Pharmacy, Thomas Jefferson University (Soni, Kaushal), Philadelphia, PA. ^[4]

关键词 amniotic fluid azithromycin obstetric pharmacology pharmacokinetics preterm premature rupture of membranes